A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs INCB 54707 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 30 May 2019 Status changed from active, no longer recruiting to completed.
- 08 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2018 Status changed from not yet recruiting to recruiting.